[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"1st-line-treatment\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:1st-line-treatment":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":38,"leadSponsor":40,"locationsCount":43},"100558405","study-of-cancer-patients-preferences-for-genetic-information-modalities-preceding-theranostic-exome-analysis-100558405",false,"NCT06550687","Study of Cancer Patients' Preferences for Genetic Information Modalities Preceding Theranostic Exome Analysis.","Study of Cancer Patients' Preferences for Genetic Information Modalities Preceding Theranostic Exome Analysis. Qualitative Observational and Interventional Cross-sectional Study","INFOGENE","Inclusion Criteria:\n\n* Patient identified for inclusion in the EXOMA 2 study (exome analysis request)\n* Available to receive different types of information\n* Fluent in French\n* No prior oncogenetic consultation\n* Having been informed of the objectives of the study and having given written non-objection to participate in the INFOGene study\n* Authorizing audio recording of consultations and interviews\n\nExclusion Criteria:\n\n* Patient who refused to participate in the EXOMA2 study (for phase 3 patients only)\n* Has a psychiatric, cognitive or neurological disorder that makes participation impossible\n* Working in the field of genetics","ALL","18 Years",{"count":20,"type":21},80,"ESTIMATED","INTERVENTIONAL",[24],"NA","Currently, the EXOMA2 study (NCT04614480) offers earlier and more comprehensive exome analysis in the management of cancer patients than EXOMA. Based on the active EXOMA2 patient file, the INFOGene study offers the opportunity to study patient-physician communication, to assess patient preferences with regard to different information modalities concerning theranostic exome analysis, and to reflect on information modalities to ensure optimal patient comprehension of the information provided.\n\nThe qualitative cross-sectional study includes a dual observational and interventional component involving cancer patients. The patients will come from the EXOMA 2 active file at Dijon University Hospital and the CGFL.",[27,28,29,30],"All Types of Metastatic Solid Malignancy","1st-line Treatment","Exome Analysis","Active File EXOMA2 Study","RECRUITING","2025-02-14",{"date":34,"type":35},"2025-02-18","ACTUAL",{"date":37,"type":35},"2024-09-19",{"date":39,"type":21},"2026-11-01",{"name":41,"class":42},"Centre Georges Francois Leclerc","OTHER",2]